- Singapore’s Thrixen raised $7M co-led by 22Health Ventures and John Ballantyne.
- Funds will advance Thrixen’s multiplex diagnostic tech platform for point-of-care testing.
- The investment provides Thrixen with US market access and guidance for clinical trials.
Healthtech haul
Singapore-based healthtech startup Thrixen has raised US$7 million in a round co-led by 22Health Ventures, an early-stage healthtech investment firm, and John Ballantyne, co-founder of biotech player Aldevron.
Thrixen plans to utilize the funds to advance the development of its groundbreaking diagnostic tech platform, capable of performing multiplex diagnostic tests at the point of care.
Market access and guidance
The proprietary assay technology boasts 99.5% sensitivity in clinical trials, replacing antibodies. In addition to capital, the investment from 22Health Ventures provides Thrixen accelerated access to the US market and management guidance.
The VC firm’s founder and managing partner, Ara Tavitian, will join Thrixen’s board, propelling the startup’s journey towards successful clinical trials and a robust regulatory package for market entry.
To read the original article: https://www.techinasia.com/sg-healthtech-firm-bags-7m-aldevron-cofounder-22health-ventures
